Literature DB >> 27016320

Heart failure event definitions in drug trials in patients with type 2 diabetes.

Abhinav Sharma1, Deepak L Bhatt2, Gonzalo Calvo3, Nancy J Brown4, Faiez Zannad5, Robert J Mentz6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27016320      PMCID： PMC5221765          DOI： 10.1016/S2213-8587(16)00049-8

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  11 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Adjudication of serious heart failure in patients from PROactive.

Authors:  Lars Rydén; Inga Thráinsdóttir; Karl Swedberg
Journal:  Lancet       Date:  2007-01-20       Impact factor: 79.321

3.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

4.  Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry.

Authors:  Matthew A Cavender; Ph Gabriel Steg; Sidney C Smith; Kim Eagle; E Magnus Ohman; Shinya Goto; Julia Kuder; Kyungah Im; Peter W F Wilson; Deepak L Bhatt
Journal:  Circulation       Date:  2015-07-07       Impact factor: 29.690

5.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

Authors:  Karen A Hicks; James E Tcheng; Biykem Bozkurt; Bernard R Chaitman; Donald E Cutlip; Andrew Farb; Gregg C Fonarow; Jeffrey P Jacobs; Michael R Jaff; Judith H Lichtman; Marian C Limacher; Kenneth W Mahaffey; Roxana Mehran; Steven E Nissen; Eric E Smith; Shari L Targum
Journal:  J Am Coll Cardiol       Date:  2014-12-29       Impact factor: 24.094

6.  Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.

Authors:  Benjamin M Scirica; Eugene Braunwald; Itamar Raz; Matthew A Cavender; David A Morrow; Petr Jarolim; Jacob A Udell; Ofri Mosenzon; KyungAh Im; Amarachi A Umez-Eronini; Pia S Pollack; Boaz Hirshberg; Robert Frederich; Basil S Lewis; Darren K McGuire; Jaime Davidson; Ph Gabriel Steg; Deepak L Bhatt
Journal:  Circulation       Date:  2014-09-04       Impact factor: 29.690

7.  Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.

Authors:  Jacob A Udell; Matthew A Cavender; Deepak L Bhatt; Saurav Chatterjee; Michael E Farkouh; Benjamin M Scirica
Journal:  Lancet Diabetes Endocrinol       Date:  2015-03-17       Impact factor: 32.069

8.  The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; Ph Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Deborah L Price; Roland Chen; Jacob Udell; Itamar Raz
Journal:  Am Heart J       Date:  2011-11       Impact factor: 4.749

9.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.

Authors:  John J V McMurray; Hertzel C Gerstein; Rury R Holman; Marc A Pfeffer
Journal:  Lancet Diabetes Endocrinol       Date:  2014-03-13       Impact factor: 32.069

10.  Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition.

Authors:  Faiez Zannad; Wendy Gattis Stough; Bertram Pitt; John G F Cleland; Kirkwood F Adams; Nancy L Geller; Christian Torp-Pedersen; Bridget-Anne Kirwan; Ferenc Follath
Journal:  Eur Heart J       Date:  2008-02       Impact factor: 29.983
View more
  8 in total

Review 1.  Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Authors:  Stephen J Greene; Muthiah Vaduganathan; Muhammad Shahzeb Khan; George L Bakris; Matthew R Weir; Jonathan H Seltzer; Naveed Sattar; Darren K McGuire; James L Januzzi; Norman Stockbridge; Javed Butler
Journal:  J Am Coll Cardiol       Date:  2018-03-10       Impact factor: 24.094

Review 2.  Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.

Authors:  Eberhard Standl; Oliver Schnell; Darren K McGuire
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

Review 3.  Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Authors:  Amir Razaghizad; Emily Oulousian; Varinder Kaur Randhawa; João Pedro Ferreira; James M Brophy; Stephen J Greene; Julian Guida; G Michael Felker; Marat Fudim; Michael Tsoukas; Tricia M Peters; Thomas A Mavrakanas; Nadia Giannetti; Justin Ezekowitz; Abhinav Sharma
Journal:  J Am Heart Assoc       Date:  2022-05-16       Impact factor: 6.106

4.  Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.

Authors:  Marat Fudim; Jennifer White; Neha J Pagidipati; Yuliya Lokhnygina; Julio Wainstein; Jan Murin; Nayyar Iqbal; Peter Öhman; Renato D Lopes; Barry Reicher; Rury R Holman; Adrian F Hernandez; Robert J Mentz
Journal:  Circulation       Date:  2019-09-23       Impact factor: 29.690

5.  Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.

Authors:  Abhinav Sharma; Andrew P Ambrosy; Adam D DeVore; Kenneth B Margulies; Steven E McNulty; Robert J Mentz; Adrian F Hernandez; Gary Michael Felker; Lauren B Cooper; Anuradha Lala; Justin Vader; John D Groake; Barry A Borlaug; Eric J Velazquez
Journal:  ESC Heart Fail       Date:  2018-08-17

Review 6.  Predictors of heart failure development in type 2 diabetes: a practical approach.

Authors:  Subodh Verma; Abhinav Sharma; Naresh Kanumilli; Javed Butler
Journal:  Curr Opin Cardiol       Date:  2019-09       Impact factor: 2.161

7.  Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.

Authors:  Abhinav Sharma; Jingjing Wu; Justin A Ezekowitz; Gary Michael Felker; Jacob A Udell; Paul A Heidenreich; Gregg C Fonarow; Kenneth W Mahaffey; Adrian F Hernandez; Adam D DeVore
Journal:  ESC Heart Fail       Date:  2019-11-20

8.  Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.

Authors:  Abhinav Sharma; Christopher P Cannon; William B White; Yuyin Liu; George L Bakris; William C Cushman; Faiez Zannad
Journal:  J Am Heart Assoc       Date:  2018-05-16       Impact factor: 5.501
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.